Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
Abstract Patients with early-stage, hormone receptor–positive breast cancer with favorable clinicopathologic features are often not recommended for extended endocrine therapy. However, even patients with T1N0 disease remain at significant risk of distant recurrence up to 15 years following 5 years o...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2017-08-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-017-0037-3 |
| _version_ | 1797641691972239360 |
|---|---|
| author | Brock Schroeder Yi Zhang Olle Stål Tommy Fornander Adam Brufsky Dennis C. Sgroi Catherine A. Schnabel |
| author_facet | Brock Schroeder Yi Zhang Olle Stål Tommy Fornander Adam Brufsky Dennis C. Sgroi Catherine A. Schnabel |
| author_sort | Brock Schroeder |
| collection | DOAJ |
| description | Abstract Patients with early-stage, hormone receptor–positive breast cancer with favorable clinicopathologic features are often not recommended for extended endocrine therapy. However, even patients with T1N0 disease remain at significant risk of distant recurrence up to 15 years following 5 years of endocrine therapy, highlighting the need for further stratification based on individualized risk to select patients for extended endocrine therapy. In this study, the incremental utility of genomic classification to stratify clinically low-risk patients for late distant recurrence was evaluated using the Breast Cancer Index. In 547 T1N0 patients from two cohorts that were disease-free at 5 years post-diagnosis, Breast Cancer Index categorized 32 and 36% from each cohort, respectively, with high risk of late distant recurrence that was associated with significantly reduced distant recurrence-free survival (86.7 and 89.6%) between years 5–15 and 5–10 compared to Breast Cancer Index low risk (95.4%; P = 0.0263 and 98.4%; P = 0.008). Findings support consideration of genomic classification in clinically low-risk hormone receptor–positive patients to identify candidates for extended endocrine therapy. |
| first_indexed | 2024-03-11T13:49:21Z |
| format | Article |
| id | doaj.art-92e90599335f479b9f2cb277f9642bd4 |
| institution | Directory Open Access Journal |
| issn | 2374-4677 |
| language | English |
| last_indexed | 2024-03-11T13:49:21Z |
| publishDate | 2017-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj.art-92e90599335f479b9f2cb277f9642bd42023-11-02T09:23:50ZengNature Portfolionpj Breast Cancer2374-46772017-08-01311310.1038/s41523-017-0037-3Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancerBrock Schroeder0Yi Zhang1Olle Stål2Tommy Fornander3Adam Brufsky4Dennis C. Sgroi5Catherine A. Schnabel6Biotheranostics, Inc.Biotheranostics, Inc.Linköping UniversityKarolinska InstituteUniversity of Pittsburgh School of MedicineMassachusetts General HospitalBiotheranostics, Inc.Abstract Patients with early-stage, hormone receptor–positive breast cancer with favorable clinicopathologic features are often not recommended for extended endocrine therapy. However, even patients with T1N0 disease remain at significant risk of distant recurrence up to 15 years following 5 years of endocrine therapy, highlighting the need for further stratification based on individualized risk to select patients for extended endocrine therapy. In this study, the incremental utility of genomic classification to stratify clinically low-risk patients for late distant recurrence was evaluated using the Breast Cancer Index. In 547 T1N0 patients from two cohorts that were disease-free at 5 years post-diagnosis, Breast Cancer Index categorized 32 and 36% from each cohort, respectively, with high risk of late distant recurrence that was associated with significantly reduced distant recurrence-free survival (86.7 and 89.6%) between years 5–15 and 5–10 compared to Breast Cancer Index low risk (95.4%; P = 0.0263 and 98.4%; P = 0.008). Findings support consideration of genomic classification in clinically low-risk hormone receptor–positive patients to identify candidates for extended endocrine therapy.https://doi.org/10.1038/s41523-017-0037-3 |
| spellingShingle | Brock Schroeder Yi Zhang Olle Stål Tommy Fornander Adam Brufsky Dennis C. Sgroi Catherine A. Schnabel Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer npj Breast Cancer |
| title | Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer |
| title_full | Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer |
| title_fullStr | Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer |
| title_full_unstemmed | Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer |
| title_short | Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer |
| title_sort | risk stratification with breast cancer index for late distant recurrence in patients with clinically low risk t1n0 estrogen receptor positive breast cancer |
| url | https://doi.org/10.1038/s41523-017-0037-3 |
| work_keys_str_mv | AT brockschroeder riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT yizhang riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT ollestal riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT tommyfornander riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT adambrufsky riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT denniscsgroi riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer AT catherineaschnabel riskstratificationwithbreastcancerindexforlatedistantrecurrenceinpatientswithclinicallylowriskt1n0estrogenreceptorpositivebreastcancer |